has been associated with IL-17A-mediated inflammatory diseases, including PsA and AS.

**Methods:** To explore the importance of IL-23 signalling in MAIT cell-derived IL-17A and IL-17F production, examine the presence of MAIT cells in psoriatic lesional skin and assess the contribution of MAIT cell-derived IL-17A and IL-17F using in vitro models of skin inflammation.

**Results:** Optimal MAIT cell IL-17A and IL-17F production occurred upon T cell receptor triggering with IL-12 and IL-18, independently of IL-23. IL-17F expression was greater at both gene and protein levels than IL-17A. The kinetics and threshold of activation for IL-17A and IL-17F suggest tighter regulation compared with other inflammatory cytokines, including IFNγ and TNF.

**Conclusion:** Optimal MAIT cell IL-17A and IL-17F production requires monocytes, which contribute to IL-12 production upon IL-18 stimulation. MAIT cells are abundant in psoriatic lesional skin. NHSFs cultured with supernatant generated from activated MAIT cells produced inflammatory mediators IL-6, IL-8 and CCL2, which were reduced upon inhibition of either IL-17A or IL-17F, with optimal suppression achieved following dual neutralisation with bimekizumab.

**Disclosure of Interests:** Suzanne Cole Employee of: UCB Pharma, Catherine Simpson Employee of: UCB Pharma, Remi Okoye Shareholder of: UCB Pharma, Employee of: UCB Pharma, Myrern Griffiths Consultant for: UCB Pharma, Employee of: UCB Pharma, Dominique Baeten Shareholder of: UCB Pharma, Employee of: UCB Pharma, Stevan Shaw Employee of: UCB Pharma, Ash Moroff Shareholder of: UCB Pharma, Employee of: UCB Pharma

**DOI:** 10.1136/annrheumdis-2019-eular.4235

**REFERENCES:**

**Acknowledgement:** Funded by UCB Pharma. The authors would like to acknowledge Alexandre Webster MSc, of iMed Comms, an Ashfield Company, for editorial support that was funded by UCB Pharma in accordance with Good Publication Practice (GPP3) guidelines. The authors acknowledge Alvaro Arjona, PhD, of UCB Pharma, for publication and editorial support.

**Disclosure of Interests:** Laure Campillo-Gimenez; None declared, Florence Castelli; None declared, Françoise Fenaire; None declared, Aurélie Prignon; None declared, Christèle Combes; None declared, Martine Cohen Solal; None declared, François Fenaille; None declared, Aurélie Prignon; None declared, Christèle Combes; None declared.